IL13 and neoplasm: Research revealed that a tandem configuration of IL13 and EphA2 scFv demonstrated that the IL13-anti-EphA2 TanCAR showed significantly enhanced anti-tumor efficacy compared to single CAR-T cells, in both in vitro and in vivo settings (282).